Forward to: Strategy Team

Competitive Landscape Analysis
Workflows

Ten agent workflows for the Strategy Team — competitor pipeline monitoring, market share analysis, pricing intelligence, therapeutic area dynamics, launch readiness assessment, KOL engagement tracking, conference intelligence, payer coverage monitoring, commercial strategy signals, and competitive strategy dashboard — enabling data-driven strategic decisions powered by comprehensive domain intelligence.

These workflows display realistic demo data for demonstration. In production, the agents connect to your real biotech and life sciences data via MCP services or CSV import.
Deployment Options
The entire platform is available as a self-hosted solution or managed service
Self-Hosted
RECOMMENDED FOR ENTERPRISE
Deploy the entire platform on your own infrastructure. Your data never leaves your environment. Bring your own LLM API key (OpenAI, Claude, Gemini) or use local LLMs. Full source code delivered.
Complete source code (Python agents, PHP dashboards, MCP services)
Data stays on your servers — no external data transfer
MCP connectors for your existing data sources, APIs, and internal platforms
Custom integration and onboarding support available
$999
2 AI Agents
5 integration hrs
$1,999
5 AI Agents
10 integration hrs
$3,999
10 AI Agents
20 integration hrs
one-time license + (optional) $999/yr updates
Managed Platform
FOR AGENCIES & TEAMS
We host and operate the platform for you. Upload data or connect your platforms via secure MCP services or using API. No infrastructure management needed.
Fully managed — no DevOps required on your side
Secure data upload or API-based MCP integration
Dashboard access with your own branded login
Automatic updates and new agent releases
$999/mo
2 AI Agents
5 integration hrs
$1,999/mo
5 AI Agents
10 integration hrs
$3,999/mo
10 AI Agents
20 integration hrs
includes hosting, updates & support
* price may be higher in cases of very high AI processing volumes/demands
Both options include MCP services with connectors for your existing data sources, APIs, and internal platforms. Data dictionaries define the schema contract between each agent and your data sources.
See example of production dashboards: Programmatic Trading AI Agent Dashboards →

1Competitor Pipeline Monitoring

AI agent monitors competitor biotech and pharma domains to provide real-time pipeline intelligence — tracking new programs, phase transitions, and strategic pivots across therapeutic areas.

1
Track Competitor Pipelines
/products/investors/pressOpenPageRank
COMPETITOR PIPELINE INTELLIGENCE — TOP 20 MONITORED ════════════════════════════════════════════════════════ pfizer.com — Oncology Pivot /products: 24 oncology programs (up from 18 last year) /investors: Oncology R&D spend: $4.2B (+35%) /press: 3 new ADC programs initiated SIGNAL: Aggressive oncology expansion post-Seagen novartis.com — Radioligand Focus /products: Pluvicto + 6 next-gen radioligands /investors: AAA acquisition driving pipeline SIGNAL: First-mover in radioligand — building franchise lilly.com — Obesity Dominance /products: Mounjaro + Zepbound + 4 next-gen obesity programs /investors: Obesity franchise revenue: $12B+ run rate SIGNAL: Incumbent advantage growing — difficult to displace

2Market Share Analysis

AI agent estimates market share dynamics by analyzing domain signals — investor presentations, pricing pages, career postings, and press releases as proxies for commercial momentum.

1
Analyze Market Share Dynamics
/investors/pricing/pressIAB Categories
MARKET SHARE ANALYSIS — PD-1/PD-L1 CHECKPOINT INHIBITORS ════════════════════════════════════════════════════════ Company Product Revenue Share Trend merck.com Keytruda $28B 52% +4pp bms.com Opdivo $9.5B 18% -2pp roche.com Tecentriq $4.2B 8% flat astrazeneca.com Imfinzi $4.8B 9% +1pp regeneron.com Libtayo $1.2B 2% +1pp MARKET DYNAMICS: Total market size: $54B and growing Keytruda dominance: Increasing — 52% share SIGNAL: Differentiation increasingly difficult in IO

3Pricing Intelligence

AI agent monitors drug pricing signals across pharma domains — list prices, net price trends, discount programs, and payer negotiation outcomes to inform pricing strategy.

1
Track Competitive Pricing
/pricing/investors/pressCountries
DRUG PRICING INTELLIGENCE ════════════════════════════════════════════════════════ OBESITY MARKET PRICING: novonordisk.com — Wegovy: $1,350/month (list) lilly.com — Zepbound: $1,060/month (list) Net price after rebates: ~$500-700/month SIGNAL: Price competition intensifying — IRA impact pending GENE THERAPY PRICING: novartis.com — Zolgensma: $2.1M per treatment bluebirdbio.com — Lyfgenia: $3.1M per treatment SIGNAL: Payer pushback on one-time gene therapy pricing IRA PRICE NEGOTIATION: First 10 drugs negotiated: 25-79% discounts Next round (2027): 15 additional drugs selected

4Therapeutic Area Dynamics

AI agent analyzes therapeutic area competitive dynamics by monitoring multiple domain signals to identify market shifts, unmet need gaps, and emerging competitive threats.

1
Analyze TA Competitive Dynamics
/products/investors/pressIAB Categories
THERAPEUTIC AREA HEAT MAP ════════════════════════════════════════════════════════ TA Market Size Growth Competition Unmet Need Oncology $220B +8% Very High Medium Obesity $100B+ +45% High High Immunology $95B +6% Very High Medium Rare Disease $45B +12% Moderate High CNS $35B +4% High Very High Cell/Gene Tx $8B +28% Moderate Very High STRATEGIC RECOMMENDATION: Prioritize: Rare disease, CNS, Cell/Gene therapy Selective: Oncology (differentiated mechanisms only) Avoid: Crowded IO, me-too GLP-1s

5Launch Readiness Assessment

AI agent assesses competitor launch readiness by monitoring pre-launch signals — commercial hiring, field force expansion, pricing page additions, and payer engagement indicators.

1
Assess Launch Readiness Signals
/careers/pricing/press/partners
COMPETITOR LAUNCH READINESS TRACKER ════════════════════════════════════════════════════════ beamtx.com — BEAM-101 (SCD) /careers: +62% commercial postings — VP Commercial hired /pricing: No pricing page yet — pre-commercial /partners: New specialty pharmacy agreement announced Launch readiness: 65/100 — 12-18 months out argenx.com — Efgartigimod (CIDP) /careers: 50 new field rep positions posted /pricing: Pricing page updated with CIDP content /press: Payer presentations at AMCP Launch readiness: 92/100 — launch imminent

6KOL Engagement Tracking

AI agent monitors key opinion leader activity by tracking academic medical center domains, conference presentations, publication activity, and advisory board signals.

1
Track KOL Activity
/leadership/events/blogOpenPageRank
KOL ENGAGEMENT INTELLIGENCE ════════════════════════════════════════════════════════ dana-farber.org /leadership: Dr. Sarah Chen — 12 competitor advisory boards /events: Speaking at ASCO, ASH, AACR (6 presentations) PageRank: 8.1 SIGNAL: Top oncology KOL heavily engaged by competitors mayoclinic.org /leadership: Dr. James Rivera — gene therapy investigator /blog: 8 publications supporting competitor product SIGNAL: KOL aligned with competitor — engagement needed KOL LANDSCAPE: Top KOLs tracked: 500 across 12 TAs Competitor-aligned KOLs: 65% of top 50 ACTION: Prioritize KOL engagement in rare disease

7Conference Intelligence

AI agent monitors medical conference domains and pharma press pages to track abstract submissions, late-breaking data presentations, and competitor conference strategies.

1
Track Conference Activity
/events/press/investorsOpenPageRank
CONFERENCE INTELLIGENCE — ASCO 2026 ════════════════════════════════════════════════════════ LATE-BREAKING ABSTRACTS DETECTED: merck.com — Keytruda perioperative NSCLC (LBA) roche.com — Tiragolumab + Tecentriq (LBA) astrazeneca.com — Dato-DXd Phase 3 (LBA) COMPETITOR CONFERENCE PRESENCE: Pfizer: 42 abstracts | Roche: 38 | Novartis: 35 Our company: 18 abstracts — below peer average UPCOMING CONFERENCES: ASCO: June 2026 | EHA: June 2026 | ESMO: Sept 2026 SIGNAL: Increase abstract submissions for key programs

8Payer Coverage Monitoring

AI agent monitors payer and PBM domains to track formulary decisions, prior authorization changes, and coverage policies affecting competitor products.

1
Track Payer Coverage Decisions
/products/press/complianceIAB Categories
PAYER COVERAGE INTELLIGENCE ════════════════════════════════════════════════════════ express-scripts.com /products: 2026 National Preferred Formulary published /press: GLP-1 coverage expanded — Zepbound added to preferred SIGNAL: Lilly gaining payer preference over Novo cvs.com — CVS Caremark /products: Specialty formulary update /press: Gene therapy coverage restricted — outcomes-based only SIGNAL: Gene therapy access barrier — outcomes contracts needed PAYER LANDSCAPE: Products gaining coverage: 24 new formulary adds Products losing coverage: 8 exclusions this cycle Prior auth trend: Increasing for specialty drugs

9Commercial Strategy Signals

AI agent detects competitor commercial strategy shifts by analyzing domain changes — new product landing pages, DTC advertising signals, patient support programs, and field force restructuring.

1
Detect Commercial Strategy Changes
/products/careers/support/press
COMMERCIAL STRATEGY INTELLIGENCE ════════════════════════════════════════════════════════ lilly.com — Obesity Commercial Expansion /products: New Zepbound patient portal launched /support: Savings card program — $25/month copay /careers: +200 field rep postings (obesity) SIGNAL: Massive commercial investment — DTC campaign imminent bms.com — Cardiovascular Restructuring /careers: -35% CV field positions posted /products: Eliquis patient support scaled down SIGNAL: Pre-LOE commercial wind-down for Eliquis COMMERCIAL TREND SIGNALS: DTC advertising spend (industry): $8.2B (+12% YoY) Digital marketing share: 42% (vs 35% last year)

10Competitive Strategy Dashboard

AI agent synthesizes all competitive intelligence into a strategy dashboard — providing leadership with positioning, threat assessment, and opportunity identification across the competitive landscape.

1
Generate Competitive Strategy Dashboard
/products/investors/pressOpenPageRankIAB Categories
COMPETITIVE DASHBOARD — FEBRUARY 2026 ════════════════════════════════════════════════════════ COMPETITIVE POSITION: Pipeline rank: #8 global (by rNPV) Market share (key TAs): 3rd in oncology, 5th in immunology Launch performance: Above peer average THREATS: New competitive entries: 14 in our key TAs Biosimilar threats: 2 products within 3 years Pricing pressure: IRA + payer negotiation OPPORTUNITIES: Unmet need gaps: 4 TAs identified Competitor weaknesses: 3 exploitable
2
Generate Competitive Report

Competitive Intelligence Report — February 2026

EXECUTIVE SUMMARY ──────────────────────────────────────── Competitors monitored: 280 domains (top 20 deep-dive) Therapeutic areas tracked: 12 major categories KOLs monitored: 500 across all TAs Payer decisions tracked: 45 this quarter KEY INSIGHTS Obesity market reshaping competitive landscape — Lilly and Novo dominating. IO market maturing — differentiation through combinations and biomarkers. Gene therapy commercial model challenges persist — outcomes-based contracts. Conference strategy needs strengthening — below peer abstract volume. KOL engagement gaps in 3 priority therapeutic areas identified.
Get in Touch

Interested in AI Agent Domain Intelligence?

For pricing, subscription options, custom database builds, or enterprise partnerships — contact us below.

Power Your AI Agents with Domain Intelligence

Subscribe to the AI Agent Domain Database — continuous access to 102M domains, 20 page types each, quarterly refreshes, and real-time change signals.

AI Agent Database View Pricing

Annual subscription includes quarterly data refreshes, change detection alerts, and priority API access.